deCODE genetics, Inc. (Íslensk erfðagreining in Icelandic) is a biopharmaceutical company based in Reykjavík, Iceland. deCODE applies its discoveries in human genetics to the development of drugs for common diseases. deCODE has isolated key genes involved in schizophrenia, cardiovascular disease and cancer. Their work represents the first time a gene has been identified (by two independent studies) to be associated with schizophrenia.

Their access to extensive population data offers the means to drug discovery and development, determination of drug response, and development of genetic screening disease. Its pharmacogenomics program promises to develop the means to predict an individual's responsiveness to practically any drug.

Kári Stefánsson is the company's co-founder and CEO.

External link

• deCODE.com

Companies in the NASDAQ Biotechnology Index | Companies of Iceland | Biotechnology companies | Pharmaceutical companies

deCODE Genetics